uniform. Recently, based on previous clustering analysis and clinical, histopathological, serological and prognostic aspects three subcategories of AAV have been proposed and named as: non-severe AAV, severe PR3-AAV and severe MPO-AAV [1].

Objectives: In line with these attempts to subcategorize AAV we decided to use latent class analysis (LCA) on a large multicenter cohort of polish AAV patients from POLVAS [2] registry to identify potential new subphenotypes or confirm already proposed ones.

Methods: Latent Class Analysis (LCA) approach was used as a model based clustering of objects described by dichotomous (e.g., gender; ANCA status – cANCA, pANCA), organ involvement - skin, eye, ENT, respiratory, heart, GI, renal, urinary, CNS, peripheral nerves) and polytomous (number of relapses) variables supported by quantitative covariates (e.g., age at diagnosis, CRP at diagnosis, maximal serum creatinine concentration ever).

Results: Results of LCA on our AAV group returned four class model of AAV subphenotypes, confirming existence of the previously proposed by Mahr at al. [1] and revealed fourth – previously not described clinically relevant subphenotype. To this fourth class - belong patients only with GPA, diagnosed at young age, with multiorgan involvement, high relapse rate and relatively high risk of death.

Table 1. AAV subcategorization – summary of clinical characteristics and ANCA specificity

<table>
<thead>
<tr>
<th>LCA Class</th>
<th>GPA</th>
<th>PR3</th>
<th>MPO</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCA Class 1</td>
<td>Mainly GPA (GPA)</td>
<td>Mainly GPA (GPA)</td>
<td>Only GPA (MPO)</td>
</tr>
<tr>
<td>LCA Class 2</td>
<td>Mainly GPA (GPA)</td>
<td>Mainly GPA (GPA)</td>
<td>Only GPA (MPO)</td>
</tr>
<tr>
<td>LCA Class 3</td>
<td>Mainly GPA (GPA)</td>
<td>Mainly GPA (GPA)</td>
<td>Only GPA (MPO)</td>
</tr>
<tr>
<td>LCA Class 4</td>
<td>Mainly GPA (GPA)</td>
<td>Mainly GPA (GPA)</td>
<td>Only GPA (MPO)</td>
</tr>
</tbody>
</table>

Conclusion: Based on multiple clinical and serological variables LCA method-ology identified 4 subphenotype models of AAV. Fourth-class is a new clinically important subphenotype including exclusively PR3-positive young AAV patients with multiorgan involvement, high risk of relapse and distinct mortality.

Disclosure of Interests: Krzysztof Wójcik: None declared, Adam Cmiel: None declared, Anna Masiak: None declared, Zbigniew Zdrojewski: None declared, Radosław Jeleniewicz: None declared, Maria Majdan Consultant of: Roche, Amgen, Speakers bureau: Roche, Amgen, Iwona Brzozko: None declared, Marek Brzozko: None declared, Piotr Gluszko: None declared, Małgorzata Stasiek: None declared, Małgorzata Wisłowska: None declared, Joanna Kur- Zalewska: None declared, Marta Madej: None declared, Anna Hawrot-Kawecka: None declared, Hanna Stonorlaw: None declared, Barbara Bułło-Piontecka: None declared, Alicja Dębska-Sliźnień: None declared, Eugeniusz Kucharz: None declared, Katarzyna Jakuszko: None declared, Jacek Musiał: None declared

DOI: 10.1136/annrheumdis-2020-eular.817

FR01025

THE CLINICAL FEATURES AND OUTCOME OF VENA CAVA INVOLVEMENT IN BEHÇET’S DISEASE

J. Zhou,1 Y. Liu,2 Y. Wang,2 W. Zheng,1 1Peking Union Medical College Hospital, Rheumatology, Beijing, China; 2Peking Union Medical College Hospital, Radiology, Beijing, China

Background: Behcet’s disease (BD) is a systemic disease that can affect vessels of any size and type. However, only limited cases of BD patients with vena cava involvement have been reported.

Objectives: To investigate the clinical features and outcome of vena cava involvement in BD patients.

Methods: We retrospectively reviewed the clinical data of BD patients with vena cava involvement in our institute from August 2001 to October 2019.

Results: Fifty BD patients with vena cava involvement were included. The median interval between BD onset and diagnosis of vena cava involvement was 2.8 (range 0–19.4) years. Superior vena cava (SVC) involvement was detected in 22 (44.0%) patients, and 21 patients had typical manifestations of SVC syndrome. Inferior vena cava (IVC) involvement was detected in 33 (70.0%) patients, including 7 patients diagnosed with Budd-Chiari syndrome. Seven patients had both superior and inferior vena cava involvement. Forty-five (90.0%) patients had venous involvement other than vena cava, including 19 patients with common iliac thrombosis, 12 patients with common femoral vein thrombosis, 11 patients with external iliac vein thrombosis, etc. For the other BD manifestations, oral ulceration was presented in all patients, followed by genital ulceration (35, 70.0%), Erythema nodosum (27, 54.0%) and pathergy reaction (25, 50.0%). Thirteen (26%) patients had eye involvement. Ten (20%) patients had pleural and/or pericardial effusions. Eleven (22.0%) patients had pulmonary thromboembolism, and 4 (8.0%) patients had arterial involvement.

Disclosure of Interests: No

DOI: 10.1136/annrheumdis-2020-eular.817

FR01024

IDENTIFICATION OF RISK AND PROGNOSTIC FACTORS FOR POLYARTERITIS NODOSA PATIENTS WITH DIGITAL GRENRENE

D. Xu,1 X. Tian,2 X. Zeng,1 F. Zhang,1 L. Zhao2, S. Zhang2, J. Zhou2, J. L. Zhao1, X. Kong1 on behalf of Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education and Department of Rheumatology, 2nd Affiliated Hospital of Dalian Medical University. 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; 22nd Affiliated Hospital of Dalian Medical University, Rheumatology, Dalian, China; 32nd Affiliated Hospital of Dalian Medical University, Dalian, China

Background: Polyarteritis nodosa (PAN) is a segmental, necrotizing vascular disease that primarily impacts medium-sized muscle arteries. The estimated annual incidence of PAN is still lacking in China. Digital gangrene is an ischemic manifestation of the limb. However, the causes and the treatment methods vary from case to case, and the outcome is unpredictable. These features emphasize the need to identify measurable variables that accelerate digital gangrene development in PAN patients. However, little effort has been made to identify the clinical and laboratory factors that affect PAN patients with digital gangrene to anticipate their natural history and response to therapy.

Objectives: Many patients with polyarteritis nodosa (PAN) complicated with digital gangrene have poor outcomes and related research information is limited. This study was carried out to identify the associated risk and prognostic factors.

Methods: We conducted a retrospective study of 148 PAN patients admitted to Peking Union Medical College Hospital (PUMCH) from September 1986 to December 2018. The characteristics, therapeutic regimens, and outcome data for patients with and without gangrene were compared. The Kaplan–Meier method and Cox hazard regression model were used to evaluate the prognostic factors.

Results: Forty-seven (31.8%) PAN patients had digital gangrene complications. The average age was 40.4±17.9 years and the average disease duration was 11 (4-27) months. The presence of digital gangrene was correlated with smoking history (odds ratio (OR), 4.27; 95% confidence interval (95% CI), 1.56-11.66) and eosinophil elevation (28.12, 10.30-76.8). Thirty-two (68.1%) gangrene patients received methylprednisolone pulse therapy and all of these patients were treated with cyclophosphamide. Nine patients suffered irreversible organ injury and two died. Disease duration ≥ 24 months and elevated serum C-reactive protein (CRP) were identified as hazardous factors for poor prognosis in patients with gangrene (P=0.003, HR=8.668, 95% CI 2.11, 35.55 and P=0.042, HR=27.062, 95% CI 1.13, 648.57, respectively).

Conclusion: Smoking history and eosinophil elevation in PAN patients were more prone to digital gangrene and high serum CRP level predicted poor outcomes. PAN patients with smoking history and elevated eosinophils need to be seriously evaluated by clinicians. Furthermore, the CRP level should be efficiently controlled for good prognosis.

References:

Disclosure of Interests: No

DOI: 10.1136/annrheumdis-2020-eular.817

FR010225